The domestic pharmaceutical bio-industry is facing difficulties in developing new drugs for atopic dermatitis. Recently, Kangstem Biotech's stem cell therapy drug completed Phase III clinical trials, but the results fell short of expectations. JW Pharmaceutical's atopic dermatitis drug candidate failed to prove its efficacy in a Phase II clinical trial.

Nevertheless, the companies’ challenge to develop atopic dermatitis drugs continues. Enzychem Lifesciences submitted an IND for Phase II trial earlier this month, and Shapreon is conducting Phase I/IIa clinical trials in Korea and the United States. SCM Life Science, Daewoong Pharmaceutical, and Novacell Technology are also developing new drugs with new me